Research Article

Sensitive Detection of Molecular Targets in Cancer by Minisequencing

Volume: 12 Number: 3 July 1, 2021
  • Şirin Yüksel Kılıçturgay
  • Cemaliye Boylu Akyerli *
TR EN

Sensitive Detection of Molecular Targets in Cancer by Minisequencing

Abstract

Purpose: Molecular alterations leading to specific mutations are essential for tumor development and survival. Accurate analysis of these molecular targets is important for diagnosis, early detection, forecasting of prognosis and aiding in treatment of different cancer types. Therefore, for sensitive analysis of molecular markers, we aimed to optimize and use minisequencing protocols besides Sanger sequencing. Methods and Materials: Sanger sequencing and minisequencing were performed for IDH1 R132, IDH2 R140/R172 and TERT promoter C228/C250 mutations using genomic DNA isolated from glioma samples. Minisequencing reactions were performed with detection primers using SnaPshot Multiplex Ready Reaction Mix and run on automated capillary electrophoresis. Multiplex peaks were analyzed with GeneMapper Software. Results: In the multiplex minisequencing analyses, peaks corresponding to wild type alleles and different mutations were detected. The presence of the peaks next to the wild type peaks point to the presence of variations in that location and the nature of the mutation can be identified according to the color. Conclusions: Identification of molecular markers in cancer is very important. Minisequencing is a reliable method for the detection of molecular targets.

Keywords

References

  1. 1. Chakravarthi BV, Nepal S, Varambally S. Genomic and Epigenomic Alterations in Cancer. Am J Pathol 2016;186(7):1724-35.
  2. 2. Nair M, Sandhu SS, Sharma AK. Cancer molecular markers: A guide to cancer detection and management. Semin Cancer Biol 2018;52(Pt 1):39-55.
  3. 3. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer- associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462(7274):739-44.
  4. 4. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011;19(1):17- 30.
  5. 5. Waitkus MS, Diplas BH, Yan H. Biological Role and Therapeutic Potential of IDH Mutations in Cancer. Cancer Cell 2018;34(2):186-195.
  6. 6. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57-70.
  7. 7. Vinagre J, Almeida A, Pópulo H, Batista R, Lyra J, Pinto V, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun 2013;4:2185.
  8. 8. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 2013;110(15):6021-6.

Details

Primary Language

English

Subjects

Biochemistry and Cell Biology (Other)

Journal Section

Research Article

Authors

Şirin Yüksel Kılıçturgay
Türkiye

Cemaliye Boylu Akyerli *
Türkiye

Publication Date

July 1, 2021

Submission Date

September 7, 2020

Acceptance Date

-

Published in Issue

Year 2021 Volume: 12 Number: 3

EndNote
Yüksel Kılıçturgay Ş, Boylu Akyerli C (July 1, 2021) Sensitive Detection of Molecular Targets in Cancer by Minisequencing. Acıbadem Üniversitesi Sağlık Bilimleri Dergisi 12 3 547–552.